491 related articles for article (PubMed ID: 26075384)
1. The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors.
Vitiazeva V; Kattla JJ; Flowers SA; Lindén SK; Premaratne P; Weijdegård B; Sundfeldt K; Karlsson NG
PLoS One; 2015; 10(6):e0130197. PubMed ID: 26075384
[TBL] [Abstract][Full Text] [Related]
2. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer.
Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N
Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498
[TBL] [Abstract][Full Text] [Related]
3. [Serous and mucinous epithelial ovarian tumors--a clinicopathologic study of 116 cases].
Giurgea NL; Pitrop M; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):389-94. PubMed ID: 23077925
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor in ovarian cyst fluid.
Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; Boonstra H; Sweep CG
Cancer; 2001 Jan; 91(2):371-7. PubMed ID: 11180084
[TBL] [Abstract][Full Text] [Related]
5. Analysis of blood group antigens on MUC5AC in mucinous ovarian cancer tissues using in situ proximity ligation assay.
Mateoiu C; Vitiazeva V; Kristjansdottir B; Weijdegård B; Örnros J; Gallini R; Kamali-Moghaddam M; Sundfeldt K; Karlsson NG
Glycobiology; 2021 Dec; 31(11):1464-1471. PubMed ID: 34459484
[TBL] [Abstract][Full Text] [Related]
6. Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.
Yousif HMA; Mohammed RAA
Curr Probl Cancer; 2019 Aug; 43(4):377-385. PubMed ID: 30446260
[TBL] [Abstract][Full Text] [Related]
7. Podocalyxin-like protein 1 expression and correlation with clinical characteristics in epithelial serous and mucinous ovarian carcinoma and tumor-like lesions.
Ye F; Hu Y; Zhou C; Hu Y; Chen H
Pathobiology; 2012; 79(6):307-13. PubMed ID: 22688257
[TBL] [Abstract][Full Text] [Related]
8. Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma.
Li Q; Liu S; Lin B; Yan L; Wang Y; Wang C; Zhang S
Int J Gynecol Cancer; 2010 Dec; 20(9):1482-9. PubMed ID: 21119363
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors.
Tashiro Y; Yonezawa S; Kim YS; Sato E
Hum Pathol; 1994 Apr; 25(4):364-72. PubMed ID: 8163269
[TBL] [Abstract][Full Text] [Related]
10. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
11. O-Linked glycome and proteome of high-molecular-mass proteins in human ovarian cancer ascites: Identification of sulfation, disialic acid and O-linked fucose.
Karlsson NG; McGuckin MA
Glycobiology; 2012 Jul; 22(7):918-29. PubMed ID: 22422444
[TBL] [Abstract][Full Text] [Related]
12. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
Saygili U; Uslu T; Erten O; Doğan E
Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
14. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
[TBL] [Abstract][Full Text] [Related]
15. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
[TBL] [Abstract][Full Text] [Related]
16. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
17. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of epidermal growth factor, transforming growth factor, and c-erbB2 in ovarian cancer.
Balcan E; Demirkiran F; Aydin Y; Sanioglu C; Bese T; Arvas M; Akçay T; Cift T
Int J Gynecol Cancer; 2012 Sep; 22(7):1138-42. PubMed ID: 22914212
[TBL] [Abstract][Full Text] [Related]
19. Expression of heparanase, Mdm2, and erbB2 in ovarian cancer.
Ginath S; Menczer J; Friedmann Y; Aingorn H; Aviv A; Tajima K; Dantes A; Glezerman M; Vlodavsky I; Amsterdam A
Int J Oncol; 2001 Jun; 18(6):1133-44. PubMed ID: 11351242
[TBL] [Abstract][Full Text] [Related]
20. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]